secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061123
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya Q3 net loss $29.1M; first patient dosed in TN-201 HCM trial
------------------------------------------------------------------

- Q3 net loss $29.1M ($0.39/share); R&D $23.1M, G&A $7.8M; cash $128.1M into H1 2025.
- First patient dosed in MyPeak-1 Phase 1b trial of TN-201 for MYBPC3-associated HCM.
- FDA cleared TN-401 IND for PKP2-ARVC and granted Fast Track designation in Nov 2023.
- Positive Phase 1 data for TN-301 (HDAC6 inhibitor) in HFpEF presented at HFSA 2023.
- EMA granted Orphan Medicinal Product designation for TN-401 in Sep 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/0000950170-23-061123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/tnya-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer